News | May 14, 2025
Sai Life Sciences FY25 PAT higher by 105% to Rs. 170 Cr
PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%
PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%
The Protect VL project was born out of a vision to reduce the environmental footprint of medical devices
Tolvaptan Tablets are indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease
Launched in Thailand, the ASEAN hub, marking an early entry into the fast-growing combination therapy market (DPP-4 and SGLT-2 inhibitor combination) with strong potential for market leadership
The company has posted net profit of Rs. 82.62 crores for the Financial Year ended March 31, 2025
The company has posted net profit of Rs. 77.60 crores for the Financial Year ended March 31, 2025
The company has posted net profit of Rs. 84.29 crores for the Financial Year ended March 31, 2025
The inspection conducted from December 16, 2024 to December 20, 2024 by the Brazil Health Regulatory Agency (ANVISA)
Scores highest PAT of Rs. 118 crore in FY25
This marks yet another milestone in our series of successful audits over the past year
Subscribe To Our Newsletter & Stay Updated
